CACarolina Giassi Alano

Carolina Giassi Alano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carolina Giassi Alano has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Full-spectrum cannabidiol-rich oil modulates behavior and neurochemical alterations in a rodent model of maple syrup urine disease

    by Isabela da Silva Lemos, Sasckia Duarte, Meline Oliveira dos Santos Morais, Carolina Giassi Alano, Laura Schmidt Quinsani, Rafaela Tezza Matiola, Flávia Saccon Niero, Lucas Candido Pedro, Zilli Réus, Flavia Karine Rigo, et al.

  • Open Access

    Resveratrol improves behavior and neurochemical parameters in rats submitted to a Maple Syrup Urine Disease chemical model

    by Pauline S. Effting, Isabela S. Lemos, Bianca Z. DE Medeiros, Laura S. Quinsani, Rejane F. Seldenreich, Rafaela T. Matiola, Carolina G. Alano, Monique C. André, Gislaine Z. Réus, Guilhian Leipnitz, et al.

    Maple syrup urine disease (MSUD) is a rare genetic disorder characterized by a deficiency of the branched-chain α-keto acid dehydrogenase enzyme complex, resulting in the accumulation of branched-chain amino acids (BCAA) in the tissues and body fluids of patients. Metabolic decompensation plays a central role in MSUD neuropathology and is associated with memory impairment, cholinergic signaling alterations, and an oxidative stress state. Resveratrol is an antioxidant molecule, playing the role of a reactive species scavenger and modulating the gene expression of antioxidant enzymes. We aimed to evaluate the resveratrol effects on behavior and neurochemical parameters in rats subjected to an MSUD protocol. Animals were divided into four groups: Saline Control, BCAA Control, Saline Resveratrol, and BCAA + Resveratrol. After 21 days of administration, the open field habituation memory test, cholinergic system activity, and oxidative stress were assessed. Resveratrol was able to improve behavior parameters, protecting against the memory loss caused by the BCAA treatment, but had no effect on the cholinergic system. Additionally, resveratrol reduced oxidative damage and enhanced catalase activity. Herein, resveratrol can be an important adjuvant treatment for MSUD, as its antioxidant properties may be beneficial in the oxidative stress and cognitive impairment associated with the disease.

  • Behavioral Alterations and Cholinergic Modulation in Zebrafish Acutely Exposed To Tyrosine

    by Isabela da Silva Lemos, Francine Fiorot Prando de Vasconcelos, Guilherme da Silva Lodetti, Carolina Giassi Alano, Flávia Karine Rigo, Rahisa Scussel, Fabio Henrique Baia, Eduardo Pacheco Rico, Emilio Luiz Streck

    Tyrosinemia type II (Richner–Hanhart syndrome) is a rare disorder caused by mutations in the TAT gene, leading to elevated blood tyrosine and impaired metabolism. It presents with oculocutaneous symptoms, retinal tyrosine crystals, and neurological issues. Elevated tyrosine disrupts brain metabolism, neurotransmitters, and neurotrophic factors, causing neuroinflammation and affecting brain function. The exact mechanism of neurological damage is unclear, and the impact of dietary intervention on cognition is uncertain. While rodent models are commonly used, zebrafish are emerging as a cost-effective, genetically similar alternative for studying tyrosinemia type II. Thus, this study aims to determine whether acute exposure of zebrafish to elevated tyrosine concentrations can reproduce early central nervous system alterations associated with tyrosinemia type II. Zebrafish were exposed via immersion to 1 mM or 2 mM tyrosine for 1–24 h, with a total of 180 animals used across assays. Behavioral analysis was conducted using the novel tank test, and cholinergic and oxidative stress markers were assessed. Brain tyrosine levels were measured centrally. Exposure to 1 mM tyrosine for 24 h resulted in the highest brain accumulation, suggesting a non-linear dose-response. Behavioral testing revealed decreased locomotor activity and exploratory behavior, and ChAT activity was reduced in both exposure groups. No significant changes were observed in oxidative stress or protein damage. These findings indicate that acute tyrosine exposure induces early behavioral and cholinergic alterations without detectable oxidative stress, supporting the use of zebrafish as a preliminary model to study early neurochemical disturbances such in tyrosinemia type II. Further studies should explore different life stages, sex-specific responses, chronic exposure, and precise tyrosine kinetics, including potential non-linear effects due to the LAT1 transporter, to clarify mechanisms underlying neurotoxicity and improve translational relevance. Graphical Abstract

  • Minocycline Protects Against Oxidative Stress in a Model of Maple Syrup Urine Disease

    by Isabela da Silva Lemos, Rejane Figueiredo Seldenreich, Carolina Giassi Alano, Laura Quinsani Schmitt, Rafaela Tezza Matiola, Ellen De Pieri, Fabricia Petronilho, Ricardo Andrez Machado-De-Ávila, Emilio Luiz Streck

    Branched-chain amino acids (BCAA) leucine, isoleucine, and valine are metabolized by complex branched-chain ketoacids dehydrogenase (BCKDH). In Maple Syrup Urine Disease (MSUD), the BCKDH complex has its activity blocked by a genetic mutation, compromising the BCAA metabolism and leading to the accumulation of these BCAA, related to neurological damage in this disease. Thus, minocycline is a broad-spectrum antibiotic, bacteriostatic, and studies have shown benefits in neurodegenerative disease progression, like reduction of oxidative stress, inflammation, and downregulation of molecular pathways, such as apoptosis. Therefore, we make the hypothesis that the minocycline can ameliorate oxidative stress in the MSUD model. For this, we used 7-day-old male rats, who were treated with BCAA (leucine 393.42 mg/kg, isoleucine 121.66 mg/kg and valine 126.4 mg/kg) or saline solution (0,9%) subcutaneously, water, or minocycline (50 mg/kg) via gavage. Our results show that the MSUD group presents an increase in DCFH oxidation and TBARS levels, as well as a decrease in sulfhydryl content, related to oxidative species production, lipid and protein damage, and minocycline treatment rescues this damage found. In antioxidant activity, we found an increase in SOD activity also, a decrease in CAT in all groups studied compared to the control group. So, our results present positive effects of minocycline in MSUD, showing a potential use in this disease; moreover, more studies are necessary to understand the role of this molecule in this disease.


  • Memantine Improves Memory and Neurochemical Damage in a Model of Maple Syrup Urine Disease

    by Isabela da Silva Lemos, Carolina Antunes Torres, Carolina Giassi Alano, Rafaela Tezza Matiola, Rejane de Figueiredo Seldenreich, Alex Paulo Zeferino Padilha, Ellen De Pieri, Pauline Souza Effting, Ricardo Andrez Machado-De-Ávila, Gislaine Zilli Réus, et al.

    Maple Syrup Urine Disease (MSUD) is a metabolic disease characterized by the accumulation of branched-chain amino acids (BCAA) in different tissues due to a deficit in the branched-chain alpha-ketoacid dehydrogenase complex. The most common symptoms are poor feeding, psychomotor delay, and neurological damage. However, dietary therapy is not effective. Studies have demonstrated that memantine improves neurological damage in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases. Therefore, we hypothesize that memantine, an NMDA receptor antagonist can ameliorate the effects elicited by BCAA in an MSUD animal model. For this, we organized the rats into four groups: control group (1), MSUD group (2), memantine group (3), and MSUD + memantine group (4). Animals were exposed to the MSUD model by the administration of BCAA (15.8 µL/g) (groups 2 and 4) or saline solution (0.9%) (groups 1 and 3) and treated with water or memantine (5 mg/kg) (groups 3 and 4). Our results showed that BCAA administration induced memory alterations, and changes in the levels of acetylcholine in the cerebral cortex. Furthermore, induction of oxidative damage and alterations in antioxidant enzyme activities along with an increase in pro-inflammatory cytokines were verified in the cerebral cortex. Thus, memantine treatment prevented the alterations in memory, acetylcholinesterase activity, 2′,7′-Dichlorofluorescein oxidation, thiobarbituric acid reactive substances levels, sulfhydryl content, and inflammation. These findings suggest that memantine can improve the pathomechanisms observed in the MSUD model, and may improve oxidative stress, inflammation, and behavior alterations. Graphical Abstract